vs

Side-by-side financial comparison of FIRST INDUSTRIAL REALTY TRUST INC (FR) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $194.8M, roughly 1.6× FIRST INDUSTRIAL REALTY TRUST INC). FIRST INDUSTRIAL REALTY TRUST INC runs the higher net margin — 75.9% vs -18.2%, a 94.2% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 10.0%).

First Potomac Realty Trust was a real estate investment trust that invested in industrial properties and business parks in the suburbs of the Washington metropolitan area. In 2017, it was acquired by Government Properties Income Trust.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

FR vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.6× larger
MDGL
$321.1M
$194.8M
FR
Growing faster (revenue YoY)
MDGL
MDGL
+200.7% gap
MDGL
210.8%
10.0%
FR
Higher net margin
FR
FR
94.2% more per $
FR
75.9%
-18.2%
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FR
FR
MDGL
MDGL
Revenue
$194.8M
$321.1M
Net Profit
$147.9M
$-58.6M
Gross Margin
Operating Margin
-18.6%
Net Margin
75.9%
-18.2%
Revenue YoY
10.0%
210.8%
Net Profit YoY
179.7%
1.4%
EPS (diluted)
$1.08
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FR
FR
MDGL
MDGL
Q1 26
$194.8M
Q4 25
$188.4M
$321.1M
Q3 25
$181.4M
$287.3M
Q2 25
$180.2M
$212.8M
Q1 25
$177.1M
$137.3M
Q4 24
$175.6M
$103.3M
Q3 24
$167.6M
$62.2M
Q2 24
$164.1M
Net Profit
FR
FR
MDGL
MDGL
Q1 26
$147.9M
Q4 25
$78.8M
$-58.6M
Q3 25
$65.3M
$-114.2M
Q2 25
$55.2M
$-42.3M
Q1 25
$48.1M
$-73.2M
Q4 24
$68.4M
$-59.4M
Q3 24
$99.4M
$-107.0M
Q2 24
$51.3M
Gross Margin
FR
FR
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
FR
FR
MDGL
MDGL
Q1 26
Q4 25
34.6%
-18.6%
Q3 25
37.0%
-39.7%
Q2 25
31.7%
-22.2%
Q1 25
31.2%
-57.8%
Q4 24
40.1%
-64.8%
Q3 24
62.6%
-187.1%
Q2 24
31.8%
Net Margin
FR
FR
MDGL
MDGL
Q1 26
75.9%
Q4 25
41.8%
-18.2%
Q3 25
36.0%
-39.8%
Q2 25
30.6%
-19.9%
Q1 25
27.2%
-53.4%
Q4 24
39.0%
-57.5%
Q3 24
59.3%
-172.0%
Q2 24
31.3%
EPS (diluted)
FR
FR
MDGL
MDGL
Q1 26
$1.08
Q4 25
$0.60
$-2.55
Q3 25
$0.49
$-5.08
Q2 25
$0.42
$-1.90
Q1 25
$0.36
$-3.32
Q4 24
$0.51
$-2.50
Q3 24
$0.75
$-4.92
Q2 24
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FR
FR
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$2.9B
$602.7M
Total Assets
$5.8B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FR
FR
MDGL
MDGL
Q1 26
Q4 25
$78.0M
$198.7M
Q3 25
$33.5M
$295.7M
Q2 25
$34.9M
$186.2M
Q1 25
$35.7M
$183.6M
Q4 24
$44.5M
$100.0M
Q3 24
$47.1M
$232.7M
Q2 24
$38.5M
Total Debt
FR
FR
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
FR
FR
MDGL
MDGL
Q1 26
$2.9B
Q4 25
$2.7B
$602.7M
Q3 25
$2.7B
$625.7M
Q2 25
$2.6B
$696.0M
Q1 25
$2.7B
$710.6M
Q4 24
$2.7B
$754.4M
Q3 24
$2.6B
$777.2M
Q2 24
$2.6B
Total Assets
FR
FR
MDGL
MDGL
Q1 26
$5.8B
Q4 25
$5.7B
$1.3B
Q3 25
$5.5B
$1.4B
Q2 25
$5.5B
$1.0B
Q1 25
$5.4B
$996.6M
Q4 24
$5.3B
$1.0B
Q3 24
$5.2B
$1.1B
Q2 24
$5.2B
Debt / Equity
FR
FR
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FR
FR
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FR
FR
MDGL
MDGL
Q1 26
Q4 25
$461.3M
$-133.5M
Q3 25
$124.6M
$79.8M
Q2 25
$126.1M
$-47.1M
Q1 25
$88.6M
$-88.9M
Q4 24
$352.5M
$-104.5M
Q3 24
$105.5M
$-67.0M
Q2 24
$107.7M
Free Cash Flow
FR
FR
MDGL
MDGL
Q1 26
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
FCF Margin
FR
FR
MDGL
MDGL
Q1 26
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Capex Intensity
FR
FR
MDGL
MDGL
Q1 26
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Cash Conversion
FR
FR
MDGL
MDGL
Q1 26
Q4 25
5.85×
Q3 25
1.91×
Q2 25
2.28×
Q1 25
1.84×
Q4 24
5.15×
Q3 24
1.06×
Q2 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FR
FR

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons